ZLAB 📈 Zai Lab - Overview
Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock • ISIN: US98887Q1040
ZLAB: Cancer, Autoimmune, Infectious, Neuroscience
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China. Web URL: https://www.zailaboratory.com
Additional Sources for ZLAB Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ZLAB Stock Overview
Market Cap in USD | 2,958m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2017-09-20 |
ZLAB Stock Ratings
Growth 5y | -37.7% |
Fundamental | -5.52% |
Dividend | - |
Rel. Strength Industry | 39.8 |
Analysts | 4.67/5 |
Fair Price Momentum | 22.99 USD |
Fair Price DCF | - |
ZLAB Dividends
No Dividends PaidZLAB Growth Ratios
Growth Correlation 3m | 26.4% |
Growth Correlation 12m | 40.6% |
Growth Correlation 5y | -83.9% |
CAGR 5y | -7.82% |
CAGR/Mean DD 5y | -0.14 |
Sharpe Ratio 12m | 0.28 |
Alpha | -26.92 |
Beta | 1.10 |
Volatility | 68.19% |
Current Volume | 116.5k |
Average Volume 20d | 671.2k |
What is the price of ZLAB stocks?
As of December 26, 2024, the stock is trading at USD 26.89 with a total of 116,500 shares traded.
Over the past week, the price has changed by +2.83%, over one month by -4.27%, over three months by +32.20% and over the past year by +4.14%.
As of December 26, 2024, the stock is trading at USD 26.89 with a total of 116,500 shares traded.
Over the past week, the price has changed by +2.83%, over one month by -4.27%, over three months by +32.20% and over the past year by +4.14%.
Is Zai Lab a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Zai Lab is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.52 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ZLAB as of December 2024 is 22.99. This means that ZLAB is currently overvalued and has a potential downside of -14.5%.
Neither. Based on ValueRay Fundamental Analyses, Zai Lab is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.52 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ZLAB as of December 2024 is 22.99. This means that ZLAB is currently overvalued and has a potential downside of -14.5%.
Is ZLAB a buy, sell or hold?
Zai Lab has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy ZLAB.
Zai Lab has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy ZLAB.
- Strong Buy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for ZLAB stock price target?
According to ValueRays Forecast Model, ZLAB Zai Lab will be worth about 25.6 in December 2025. The stock is currently trading at 26.89. This means that the stock has a potential downside of -4.91%.
According to ValueRays Forecast Model, ZLAB Zai Lab will be worth about 25.6 in December 2025. The stock is currently trading at 26.89. This means that the stock has a potential downside of -4.91%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 51.8 | 92.7% |
Analysts Target Price | 72.2 | 168.6% |
ValueRay Target Price | 25.6 | -4.9% |